Építés alatt – nem éles oldal
Belépés
Leállítva1. fázis

Dose Escalation and Expansion Study of SAR443216 in Participants With Relapsed/Refractory HER2 Expressing Solid Tumors

A legfontosabb adatok

Ki végzi
Sanofi
Hol
Houston (Egyesült Államok)A helyszín megnézéseMég 5 másik országban, 10 helyszínen
Állapot
Leállítva
Fázis
1. fázis
Résztvevők
44 fő vett részt
Kezdés
2021. aug. 16.
Befejezés
2024. jan. 15.
A vizsgálat típusa
Beavatkozással járó, 5 csoport
A vizsgált kezelések
  • SAR443216 IV
  • SAR443216 SC
A regiszteradat frissítve
2025. szeptember 15.

Ki vehet részt

Életkor
18 év felett
Nem
Nők és férfiak
Egészséges önkéntesek
Nem vehetnek részt

A regiszter feltételei, szó szerint

Mind a 16 feltétel megnézéseKevesebb

Ki vehet részt

  • Participants must be ≥ 18 years of age
  • Histologically or cytologically confirmed diagnosis of metastatic solid tumors
  • Eastern Cooperative Oncology Group (ECOG) performance status 0-1
  • All participants should have at least 1 measurable disease per RECIST v1.1. An irradiated lesion can be considered measurable only if progression has been demonstrated on the irradiated lesion
  • Body weight within [45 - 150 kg] (inclusive)
  • All Contraceptive use by men and women should be consistent with local regulations regarding the methods of contraception for those participating in clinical studies
  • Capable of giving signed informed consent

Ki nem vehet részt

  • Prior solid organ or hematologic transplant
  • Participation in a concurrent clinical study in the treatment period
  • Any clinically significant cardiac disease
  • History of or current interstitial lung disease or pneumonitis
  • Uncontrolled or unresolved acute renal failure
  • Known positivity with human immunodeficiency virus (HIV), known active hepatitis A, B, and C, or uncontrolled chronic or ongoing infectious requiring parenteral treatment
  • Participant not suitable for participation, whatever the reason, as judged by the Investigator, including medical or clinical conditions; The above information is not intended to contain all considerations relevant to the potential participation in a clinical trial
  • Receipt of a live-virus vaccination within 28 days of planned treatment start
  • Inadequate hematologic, hepatic and renal function

Helyszínek itt: Egyesült Államok

Még 5 másik országban, 10 helyszínen

  • ~University of Texas - MD Anderson Cancer Center Site Number : 8400002Houston, Egyesült Államok

A vizsgálatról

Mit akar kideríteni a vizsgálat

Primary Objectives:

A teljes eredeti leírásKevesebb

Part 1 (Dose Escalation)

* To determine the MTD/maximum administered dose (MAD) of SAR443216 administered as a single agent in participants with HER2 expressing solid tumors and determine the RD(s) for intravenous (IV) and subcutaneous (SC) administration in the dose escalation part. * To determine the safety of SAR443216 after intravenous (IV) and subcutaneous (SC) administration.

Part 2 (Dose expansion)

• To assess preliminary clinical activity of single agent SAR443216 at the RD(s) in participants with HER2 expressing solid tumors, with various levels of HER2 expression.

Secondary Objectives:

Part 1 • To assess preliminary clinical activity of single agent SAR443216 after IV and SC administration at the RD(s) in participants with HER2 expressing solid tumors, with various levels of HER2 expression.

Part 2

• To determine the safety of SAR443216.

Part 1 and 2

* To characterize the pharmacokinetic (PK) profile of SAR443216 when administered as a single agent after IV and SC (Part 1 only) administration. * To evaluate the immunogenicity of SAR443216 after IV and SC administration. * To assess preliminary clinical activity of single agent SAR443216 at the RD(s) in participants with HER2 expressing solid tumors, with various levels of HER2 expression.

A vizsgálat 5 csoportja

  • SAR443216-Dose EscalationA vizsgált kezelés

    Participants with metastatic solid tumors that express HER2 in tumor tissue and/or with HER2 aberration will receive SAR443216 as intravenous (IV) infusion or subcutaneous (SC) injection.

    Kezelés: SAR443216 IV és SAR443216 SC

  • SAR443216-Dose Expansion - metastatic breast cancers with HER2 high expression: Cohort AA vizsgált kezelés

    Participants with metastatic breast cancers with HER2 high expression (with amplification) will receive SAR443216 as intravenous (IV) infusion.

    Kezelés: SAR443216 IV

  • SAR443216-Dose Expansion- metastatic breast cancers with HER2 low expression: Cohort BA vizsgált kezelés

    Participants with metastatic breast cancers with HER2 low expression or HER2 mutation (without amplification) will receive SAR443216 as intravenous (IV) infusion.

    Kezelés: SAR443216 IV

  • SAR443216-Dose Expansion- metastatic gastric cancers with HER2 low expression: Cohort CA vizsgált kezelés

    Participants with metastatic gastric cancers with HER2 low expression or HER2 mutation (without amplification) will receive SAR443216 as intravenous (IV) infusion.

    Kezelés: SAR443216 IV

  • SAR443216-Dose Expansion - metastatic NSCLC with HER2 low or high expression: Cohort DA vizsgált kezelés

    Participants with metastatic NSCLC with HER2 low or high expression and/or HER2 mutation will receive SAR443216 as intravenous (IV) infusion.

    Kezelés: SAR443216 IV

Adatok és források

Regiszteradat
Szerepel a ClinicalTrials.gov-on és az EU hivatalos vizsgálati nyilvántartásában (CTIS).
Hivatalos cím
A Phase 1/1b Open-label, First-in-human, Single Agent, Dose Escalation and Expansion Study for the Evaluation of Safety, Pharmacokinetics, Pharmacodynamics, and Anti-tumor Activity of SAR443216 in Participants With Relapsed/Refractory HER2 Expressing Solid Tumors.
A regiszteradat frissítve
2025. szeptember 15.